Literature DB >> 36066836

What is the Economic Cost of Providing an All Wales Postpartum Haemorrhage Quality Improvement Initiative (OBS Cymru)? A Cost-Consequences Comparison with Standard Care.

Megan Dale1, Sarah F Bell2, Susan O'Connell3, Cerys Scarr4, Kathryn James2, Miriam John5, Rachel E Collis2, Peter W Collins6, Grace Carolan-Rees7.   

Abstract

BACKGROUND AND
OBJECTIVE: A postpartum haemorrhage quality improvement initiative (the Obstetric Bleeding Strategy for Wales [OBS Cymru]), including about 60,000 maternities, was adopted across Wales (2017-2018). We performed a cost-consequences analysis to inform ongoing provision and wider uptake.
METHODS: Analysis was based on primary data from the All Wales postpartum haemorrhage database, with a UK National Health Services perspective, a time horizon from delivery until hospital discharge and no discounting. Costs were based on UK published sources with viscoelastic haemostatic assay costs provided by the OBS Cymru national team. Mean costs per eligible patient (postpartum haemorrhage > 1000 mL) were calculated for OBS Cymru, using the early implementation period as a comparator. Modelling allowed comparisons of three scenarios (two predefined and one post hoc) and implementation in different sizes of maternity unit.
RESULTS: All analyses demonstrated consistent savings in blood products, critical care and haematology time, and also a reduced occurrence of massive postpartum haemorrhage (> 2500 mL). Incremental postnatal length of stay varied between scenarios, substantially impacting on total costs. Mean incremental cost of OBS Cymru, compared with standard care, across Wales was £18.41 per patient (postpartum haemorrhage > 1000 mL) or - £10.66 if the length of stay was excluded. Modelling a maternity unit of 5000 births per annum, OBS Cymru incurred an incremental cost of £9.53 per patient with postpartum haemorrhage > 1000 mL.
CONCLUSIONS: OBS Cymru reduces the occurrence of massive postpartum haemorrhage, need for transfusions, quantity of blood products and intensive care. In medium-to-large maternity units (>3000 maternities per annum), the OBS Cymru intervention approaches cost neutrality compared to standard care.
© 2022. The Author(s).

Entities:  

Year:  2022        PMID: 36066836     DOI: 10.1007/s41669-022-00362-2

Source DB:  PubMed          Journal:  Pharmacoecon Open        ISSN: 2509-4262


  18 in total

1.  Carbetocin versus oxytocin for prevention of post-partum haemorrhage at caesarean section in the United Kingdom: An economic impact analysis.

Authors:  Helen A van der Nelson; Tim Draycott; Dimitrios Siassakos; Christopher W H Yau; Anthony J Hatswell
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2017-01-03       Impact factor: 2.435

2.  A prospective cohort study evaluating the cost-effectiveness of carbetocin for prevention of postpartum haemorrhage in caesarean sections.

Authors:  Yasmin Luni; Aditya Borakati; Arti Matah; Katie Skeats; Padma Eedarapalli
Journal:  J Obstet Gynaecol       Date:  2017-03-20       Impact factor: 1.246

Review 3.  Management of postpartum haemorrhage: from research into practice, a narrative review of the literature and the Cardiff experience.

Authors:  P W Collins; S F Bell; L de Lloyd; R E Collis
Journal:  Int J Obstet Anesth       Date:  2018-08-25       Impact factor: 2.603

4.  Introduction of an algorithm for ROTEM-guided fibrinogen concentrate administration in major obstetric haemorrhage.

Authors:  S Mallaiah; P Barclay; I Harrod; C Chevannes; A Bhalla
Journal:  Anaesthesia       Date:  2014-10-07       Impact factor: 6.955

5.  The incidence, aetiology, and coagulation management of massive postpartum haemorrhage: a two-year national prospective cohort study.

Authors:  S F Bell; R E Collis; C Bailey; K James; M John; K Kelly; T Kitchen; C Scarr; E Macgillivray; P W Collins
Journal:  Int J Obstet Anesth       Date:  2021-03-26       Impact factor: 2.603

6.  Reduction in massive postpartum haemorrhage and red blood cell transfusion during a national quality improvement project, Obstetric Bleeding Strategy for Wales, OBS Cymru: an observational study.

Authors:  Sarah F Bell; Rachel E Collis; Philip Pallmann; Christopher Bailey; Kathryn James; Miriam John; Kevin Kelly; Thomas Kitchen; Cerys Scarr; Adam Watkins; Tracey Edey; Elinore Macgillivray; Kathryn Greaves; Ingrid Volikas; James Tozer; Niladri Sengupta; Iolo Roberts; Claire Francis; Peter W Collins
Journal:  BMC Pregnancy Childbirth       Date:  2021-05-15       Impact factor: 3.007

7.  Designing and implementing an all Wales postpartum haemorrhage quality improvement project: OBS Cymru (the Obstetric Bleeding Strategy for Wales).

Authors:  Sarah Frances Bell; Thomas Kitchen; Miriam John; Cerys Scarr; Kevin Kelly; Christopher Bailey; Kathryn James; Adam Watkins; Elinore Macgillivray; Tracey Edey; Kathryn Greaves; Ingrid Volikas; James Tozer; Niladril Sengupta; Claire Francis; Rachel Collis; Peter Collins
Journal:  BMJ Open Qual       Date:  2020-04

8.  Viscoelastometric-guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2, a double-blind randomized controlled trial.

Authors:  P W Collins; R Cannings-John; D Bruynseels; S Mallaiah; J Dick; C Elton; A D Weeks; J Sanders; N Aawar; J Townson; K Hood; J E Hall; R E Collis
Journal:  Br J Anaesth       Date:  2017-09-01       Impact factor: 9.166

9.  Tranexamic acid for treatment of women with post-partum haemorrhage in Nigeria and Pakistan: a cost-effectiveness analysis of data from the WOMAN trial.

Authors:  Bernadette Li; Alec Miners; Haleema Shakur; Ian Roberts
Journal:  Lancet Glob Health       Date:  2018-02       Impact factor: 38.927

10.  Peripartum hysterectomy: an economic analysis of direct healthcare costs using routinely collected data.

Authors:  F A Achana; K M Fleming; L J Tata; A A Sultan; S Petrou
Journal:  BJOG       Date:  2017-11-16       Impact factor: 6.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.